The grant of composition of matter patent in the US for ridinilazole for the treatment of C. difficile infection strengthens the group’s IP portfolio. C. difficile is established as a major healthcare threat, with around 900,000 cases per annum in Europe and North America. Recurrent disease represents a key clinical issue with up to 30% of patients at risk of recurrent disease after the initial episode. Ridinilazole met its primary objective in a Phase II trial in November, demonstrating a super ....
29 Apr 2016
US patent granted for ridinilazole
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
US patent granted for ridinilazole
The grant of composition of matter patent in the US for ridinilazole for the treatment of C. difficile infection strengthens the group’s IP portfolio. C. difficile is established as a major healthcare threat, with around 900,000 cases per annum in Europe and North America. Recurrent disease represents a key clinical issue with up to 30% of patients at risk of recurrent disease after the initial episode. Ridinilazole met its primary objective in a Phase II trial in November, demonstrating a super ....